AC Immune (ACIU) Could Be Under Pressure Following Eli Lilly Sola Failure - Leerink
- Goldman sends Dow to record high, techs lift S&P, Nasdaq
- Oil hits 16-month high in buying rush after OPEC agreement
- Consolidated Communications (CNSL) to Acquire FairPoint Communications (FRP) in $1.5B Deal
- Pre-Open Stock Movers 12/05: (FRP) (GMED) (CHK) Higher; (CERC) (HDSN) (MRVL) Lower (more...)
- Burberry rejects multiple takeover offers from Coach: Financial Times
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Leerink Partners analyst Paul Matteis sees AC Immune SA (NASDAQ: ACIU) under pressure today after Eli Lilly announced that announced that its EXPEDITION3 study of solanezumab in Alzheimer's did not meet its primary endpoint; the study showed (likely a very small) trend on cognition (p=.095).
Matteis commented, "We expect ACIU shares to be under pressure today given the perceived read-through from the solanezumab (sola) result; however, we see specific differences between sola and crenezumab, and perceive the latter as much more similar to BIIB's aducanumab. While we will look to our model and assumptions once the full sola data are presented at CTAD on December 8th, our current 40% probability-of-success for crenezumab already balances optimism surrounding product profile/ph3 design while considering meaningful outstanding risk. And at a fully diluted market cap of ~$800MM (as of yesterday's close), we believe the stock implicitly assumes both a lower probability than this for crenezumab and little credit for ACIU's pipeline, which includes 4 partnered and 1 wholly owned clinical-stage asset."
The firm maintained an Outperform rating on ACIU.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Street Watchdog Research Lowers Price Target on Dollar General (DG) to $55
- Mizuho Securities Raises Price Target on PDC Energy (PDCE) to $81; Reiterates Neutral
- Spark Therapeutics (ONCE) SPK-9001 FIX Levels Still Best-in-Class But More Steroid Use - Jefferies
Create E-mail Alert Related CategoriesAnalyst Comments, FDA, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!